The UK MHRA has granted marketing authorisation to Bavarian Nordic's Vimkunya vaccine for preventing the chikungunya virus.

Bavarian Nordic is successfully navigating a sentiment-changing vaccine landscape, posting Q1 revenues significantly up from ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bavarian Nordic’s Vimkunya (recombinant, adsorbed ...

Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has ...

COPENHAGEN, Denmark, May 9, 2025 - Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Bavarian Nordic's Vimkunya (recombinant, adsorbed) vaccine for preventing chikungunya virus ...

Bavarian Nordic is targeting launch of the vaccine in the UK during the summer of 2025. “Chikungunya mostly represents a risk for UK citizens traveling overseas to affected regions in the ...

Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the ...

The United States Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP) has recommended Bavarian Nordic’s recombinant vaccine for the prevention of ...

Bavarian Nordic is targeting launch of the vaccine in the UK during the summer of 2025. “Chikungunya mostly represents a risk for UK citizens traveling overseas to affected regions in the Americas, ...